24/7 Wall St. loves companies which send capital back to shareholders via dividends. With all of the uncertainty in today’s markets and in the fluctuating economy, having a solid dividend policy may…
We are now just about two weeks away from the king of biotech and pharma events in cancer treatments. The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) is set…
When we issued our earnings previews for the week ahead, it looked as though Dendreon Corporation (NASDAQ: DNDN) had a chance of really setting the trend for the entire biotech sector this…
Earnings season is in full swing and we have many key reports due in the coming week. 24/7 Wall St. has provided some detailed previews for the key earnings reports we expect…
AuthorDendreon Corp. (NASDAQ: DNDN), maker of prostate cancer drug Provenge, is once again rumored to be a takeover target. As Streetinsider.com points out, the company’s new chairman presided over the Eli Lilly…
You might have already heard the reports that Apple is sitting on a lot of cash, around the $100 billion mark. You might have even read the scores of recommendations about what…
The three major US equities indexes opened sharply lower this morning and the slide continued pretty much without interruption all day. About half an hour before closing, all three indexes are down…
Jon OggThese are some of this Tuesday’s top analyst upgrades, downgrades, and initiations seen in Wall Street research calls. Amgen Inc. (NASDAQ: AMGN) Cut to Market Perform at Bernstein. Annaly Capital Management, Inc. (NYSE:…
The Pharmaceutical Research and Manufacturers of America (PhRMA) has spoken out against the new 2013 budget proposed by President Obama. PhRMA represents leading pharmaceutical research and biotechnology companies and some of the…
The three major US stock indexes opened a bit higher this morning, and after some volatility have managed to get to the final half hour of trading with a modest gain. Some…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Thursday morning. Amgen Inc. (NASDAQ: AMGN) Cut to Perform at Oppenheimer; named…
A US drug advisory panel today denied by a 12-1 vote permission for Amgen Inc. (NASDAQ: AMGN) to market its Xgeva prostate cancer as a treatment for slowing the spread of tumors…
Paul Ausick Credit Suisse is making a change in its Global Biotechnology outlook and says the is ‘room to run on generalist interest.’ Biogen Idec Inc. (NASDAQ: BIIB) is named as Credit Suisse’s preferred choice in…
All three major indexes opened higher this morning, but the strength didn’t last as the Chicago PMI number failed to meet expectations and came in lower even than last month’s reading. The…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Tuesday morning. Amgen Inc. (NASDAQ: AMGN) Reiterated Buy and Raised target to…
